RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
DON'T BUY

Pfizer Inc(PFE)

Apr 21, 2010
Pharma model, i.e. spending a boatload of money developing drugs and getting it into market, is really stumbling. Then the clock starts ticking with generics coming in down the road. Lipitor expires next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$16.60

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Apr 14, 2010
Their big drug Lipitor comes off patent next year, which will be a lot of revenue that will be difficult to replace. Have an “OK” pipeline. Because of their size, it takes a huge blockbuster drug to turn the needle to a positive direction.
Photo of Don LatoDon LatoUnlock Rating
$17.07

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Apr 12, 2010
$2 in annualized earnings. Very cheap stock. Doesn't have the growth that it used to. Have global growth and is a beneficiary of the decline in the US$.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$17.29

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 08, 2010
Like it for its dividend of about 4.1%. Very high cash flow. Have diversified their product line with the acquisition of Wyeth.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$17.14

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Apr 05, 2010
(Market Call Minute) If it came down a little bit be would be much more interested.
Photo of Benj GallanderBenj GallanderUnlock Rating
$16.90

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2010
Great company with a great yield and trading at a very low multiple. Pharmaceutical industry made so much money on their blockbuster drugs but that dried up. This company has made some good acquisitions and are continuing to cut costs. Pipeline is reasonable but you're not going to see the big blockbuster drugs in the next several years.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$17.39

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 24, 2010
Wouldn't own any US pharmaceutical companies. Research pipeline cupboard is really bare. Doesn't see any growth. A lot of generic competition.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 23, 2010
Pfizer (PFE-N) and Merck (MRK-N) are pretty fully priced at current levels. Growth prospects are not that great, especially with a lot of drugs coming off patent. Multiple looks attractive and dividend looks okay but there are better places to go in pharmaceuticals. Prefers Abbott Labs (ABT-N).
Photo of Don LatoDon Lato
No
Unlock Rating
$17.54

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Feb 17, 2010
One of the mega pharmas that is having trouble getting traction because it is so large. They have a problem with one of their large drugs (25% of business) coming off patent within the next year. He would look elsewhere. J&J, Abbot, are better picks.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$17.67

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 03, 2010
Model price of $29.40, a 53% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.62

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 03, 2010
Just reported lower-than-expected earnings. Chart shows a strong upward trend so technically it still looks good. Usually healthcare stocks do very well from July to October.
Photo of Don VialouxDon VialouxUnlock Rating
$18.62

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 28, 2010
(A Top Pick Jan 27/09. Up 25.12%.) Likes the outlook for drug stocks. Still a Buy.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.63

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 14, 2010
Have their challenges with patent expiries but a huge global player with very good exposure to emerging markets. Reasonable dividend. 3.7% yield.
Photo of Jeff BlackJeff BlackUnlock Rating
$19.38

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 13, 2010
Loss of their Lipitor patent in 2011 (25% of revenues) is priced into the stock but this is a problem with all Pharma plays. Patent expirations is hugely punitive. (See Top Picks.)
Photo of Gordon ReidGordon ReidUnlock Rating
$19.21

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 23, 2009
(A Top Pick Jan 27/09. Up 17.5%.) The world hated pharmaceutical stocks but started to like them more. All the major pharmas have patents coming off in the next 5 years. This is already built into the price. Companies have all built up big cash reserves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.58

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 451 to 465 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica